Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Role of thoracic ultrasonography in pleurodesis pathways for malignant pleural effusions (SIMPLE): an open-label, randomised controlled trial

Psallidas I. et al, (2022), The Lancet Respiratory Medicine, 10, 139 - 148

Pleural Fluid Has Pro-Growth Biological Properties Which Enable Cancer Cell Proliferation.

Asciak R. et al, (2021), Frontiers in oncology, 11

Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments

Kanellakis NI. et al, (2020), Thorax, 75, 1004 - 1008

Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study

Corcoran JP. et al, (2020), European Respiratory Journal, 56, 2000130 - 2000130

Antibiotic Review Kit for Hospitals (ARK-Hospital): study protocol for a stepped-wedge cluster-randomised controlled trial

Walker AS. et al, (2019), Trials, 20

Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial.

Luengo-Fernandez R. et al, (2019), The European respiratory journal, 54

Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial

Brims F. et al, (2019), Thorax, 74, 354 - 361

Randomised Ambulatory Management of Primary Pneumothorax (RAMPP): protocol of an open-label, randomised controlled trial

Hallifax R. et al, (2019), BMJ Open Respiratory Research, 6, e000403 - e000403

Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients.

Kanellakis NI. et al, (2019), BMJ open respiratory research, 6

THE BIOLOGICAL EFFECT OF TISSUE PLASMINOGEN (T-PA) ACTIVATOR AND DNASE INTRAPLEURAL DELIVERY IN PLEURAL INFECTION PATIENTS

Kanellakis NI. et al, (2018), THORAX, 73, A243 - A243

The patient perspective of treatment for Malignant Pleural Effusion (MPE)- results of a pilot service-evaluation questionnaire.

Seymour J. et al, (2018), EUROPEAN RESPIRATORY JOURNAL, 52

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis

Psallidas I. et al, (2018), The Lancet Oncology, 19, 930 - 939

Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion

Mishra EK. et al, (2018), American Journal of Respiratory and Critical Care Medicine, 197, 502 - 508

Prospective Validation of The RAPID Clinical Risk Prediction Score in Patients with Pleural Infection: The Pleural Infection Longitudinal Outcome Study (PILOT)

Corcoran JP. et al, (2018), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 197

Survival And Pleurodesis Response Markers In Malignant Pleural Effusion-The Promise Study

Psallidas I. et al, (2018), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 197

Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial.

Psallidas I. et al, (2017), BMJ open respiratory research, 4

The Third Therapeutic Intervention In Malignant Effusion Trial (time3): A Randomised Controlled Trial To Assess Dyspnea Relief And Pleurodesis Success Following Intrapleural Urokinase In Patients With Non-Draining Malignant Pleural Effusion

Mishra EK. et al, (2016), AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 193

Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion

Rahman NM. et al, (2015), JAMA, 314, 2641 - 2641

Setting up a respiratory trials unit

RAHMAN NM. et al, (2011), Respirology, 16, 64 - 68

Include forthcoming?